PTK2 and cancer: FAK inhibitors can synergistically increase the sensitivity of various cancers to chemotherapeutic agents because they not only reduce FAK expression (Le Large et al., 2021; Tong et al., 2022) but also inhibit numerous signaling pathways associated with FAK.